Literature DB >> 1386578

In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.

R Berni1, F Formelli.   

Abstract

The synthetic retinoid fenretinide (4-HPR; N-[4-hydroxyphenyl] all-trans-retinamide) interacts with plasma apo-retinol-binding protein (RBP) to form a tight complex (K'd approximately 0.2 microM) which does not exhibit binding affinity to transthyretin (TTR). Therefore, a substantial modification of the retinol hydroxyl group does not appear to affect the interaction with RBP but does drastically interfere with the protein-protein recognition. The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386578     DOI: 10.1016/0014-5793(92)81046-o

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

1.  Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.

Authors:  Konstantin Petrukhin
Journal:  Drug Discov Today Ther Strateg       Date:  2013

2.  Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo.

Authors:  Kari Nieto; Susan R Mallery; Steven P Schwendeman
Journal:  Int J Pharm       Date:  2020-06-07       Impact factor: 5.875

3.  Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.

Authors:  Xiao Wu; Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Maynard P Phelps; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2012-03-06       Impact factor: 4.939

Review 4.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina.

Authors:  Marcin Golczak; Akiko Maeda; Grzegorz Bereta; Tadao Maeda; Philip D Kiser; Silke Hunzelmann; Johannes von Lintig; William S Blaner; Krzysztof Palczewski
Journal:  J Biol Chem       Date:  2008-01-14       Impact factor: 5.157

Review 6.  The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates.

Authors:  Made Airanthi K Widjaja-Adhi; Marcin Golczak
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-11-23       Impact factor: 4.698

Review 7.  Novel therapeutics for Stargardt disease.

Authors:  Louise J Lu; Ji Liu; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-11       Impact factor: 3.117

8.  Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo.

Authors:  Alykhan Motani; Zhulun Wang; Marion Conn; Karen Siegler; Ying Zhang; Qingxiang Liu; Sheree Johnstone; Haoda Xu; Steve Thibault; Yingcai Wang; Pingchen Fan; Richard Connors; Hoa Le; Guifen Xu; Nigel Walker; Bei Shan; Peter Coward
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

9.  Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice.

Authors:  Nimesh Mody; Timothy E Graham; Yuki Tsuji; Qin Yang; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-02-19       Impact factor: 4.310

10.  A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.

Authors:  Nicoleta Dobri; Qiong Qin; Jian Kong; Kazunori Yamamoto; Zhao Liu; Gennadiy Moiseyev; Jian-Xing Ma; Rando Allikmets; Janet R Sparrow; Konstantin Petrukhin
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.